Vitrafy Life Sciences Ltd
Vitrafy Life Sciences Limited is an Australia-based company.
The business
Vitrafy Life Sciences Limited is an Australia-based company. The Company is engaged in the research, development and commercialization of its vertically integrated cryopreservation solution that includes cryopreservation medical devices (freezer, thawer and packaging solutions), LifeChain integrated software system, and application services for identified application areas in human health and animal health services. The Company has developed a proprietary range of smart cryopreservation hardware and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution. Its Lifechain software platform combines the advanced software functions, such as artificial intelligence (AI), machine learning and IoMT integration, to ensure supply chain processes are controlled, traced, tracked and monitored to the standards, and retain the quality of precious biomaterials.
Small Caps Research
No research on Vitrafy Life Sciences Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise VFY based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news

Vitrafy Life Sciences Enters US Cell and Gene Therapy Space with Cryopreservation Agreement
Vitrafy Life Sciences nets first North American cell/gene therapy deployment with Charter Medical to install its cryopreservation ecosystem (six-month term).

Vitrafy Life Sciences Raising $30m to Scale Guardion Production and US Expansion
Vitrafy Life Sciences raises $30m to scale Guardion production and accelerate US expansion amid US blood market demand.

Vitrafy Life Sciences Strikes US Partnership to Promote Cryopreservation Ecosystem for Red Blood Cells
Vitrafy inks US Vitalant pact to deploy next-gen cryopreservation for red blood cells as glycerol tech ends by 2027; signals early market traction.

Vitrafy Life Sciences Reports Strong US Army Platelet Preservation Results
Vitrafy Life Sciences announces 94% post-thaw platelet recovery with 3% DMSO no-wash protocol, independent validation for frozen platelets.
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.